Kangstem Biotech Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,969	2,767	5,856	4,681	7,542
Short-Term Investments	36,600	15,500	31,504	31,008	39,018
Trading Asset Securities	-	-	-	988.82	10,026
Cash & Short-Term Investments	38,569	18,267	37,360	36,678	56,585
Cash Growth	111.14%	-51.11%	1.86%	-35.18%	49.17%
Accounts Receivable	438.78	517.34	721.6	1,567	1,225
Other Receivables	432.35	3,800	411.99	651.07	326.35
Receivables	1,071	5,247	1,134	2,218	1,551
Inventory	814.51	858.3	578.26	467.15	763.77
Prepaid Expenses	381.26	320	330.83	330.06	326.96
Other Current Assets	2,798	3,836	7,963	6,213	6,128
Total Current Assets	43,634	28,528	47,366	45,907	65,355
Property, Plant & Equipment	17,862	19,299	29,572	31,265	34,126
Long-Term Investments	2,147	5,607	2,950	1,833	2,198
Goodwill	7,264	-	-	-	-
Other Intangible Assets	9,212	975.71	440.12	1,041	991.53
Long-Term Accounts Receivable	-0	0	-0	-0	-0
Other Long-Term Assets	1,375	1,576	925.66	546.68	477.68
Total Assets	81,493	55,986	81,253	80,592	103,148
Accounts Payable	279.18	185.84	324.27	406.56	850.37
Accrued Expenses	376.14	289.78	483.99	436.08	421.19
Short-Term Debt	4,755	3,330	2,616	2,566	2,264
Current Portion of Long-Term Debt	780	400	5,530	3,700	3,500
Current Portion of Leases	322.88	317.69	808.9	752.43	844.37
Current Unearned Revenue	330	330	330	334.05	235.77
Other Current Liabilities	1,462	2,879	8,501	6,072	9,074
Total Current Liabilities	8,305	7,732	18,594	14,267	17,191
Long-Term Debt	2,200	2,980	3,380	5,230	5,630
Long-Term Leases	1,342	1,428	1,274	1,120	1,805
Pension & Post-Retirement Benefits	-	-	1,507	970.8	913.72
Other Long-Term Liabilities	586.14	663.31	6,375	6,301	6,323
Total Liabilities	12,433	12,804	31,130	27,890	31,862
Common Stock	47,027	28,027	27,969	18,969	18,969
Additional Paid-In Capital	191,691	174,869	174,895	163,374	163,374
Retained Earnings	-177,368	-166,886	-159,354	-137,201	-117,054
Comprehensive Income & Other	7,296	7,172	4,469	4,194	2,751
Total Common Equity	68,645	43,182	47,978	49,336	68,039
Minority Interest	415.2	-	-3,494	-2,110	-2,070
Shareholders' Equity	69,060	43,182	50,123	52,702	71,286
Total Liabilities & Equity	81,493	55,986	81,253	80,592	103,148
Total Debt	9,400	8,456	13,609	13,369	14,044
Net Cash (Debt)	29,169	9,811	23,751	23,309	42,542
Net Cash Growth	197.32%	-58.69%	1.90%	-45.21%	115.13%
Net Cash Per Share	420.20	173.97	584.98	614.40	1527.64
Filing Date Shares Outstanding	69.42	56.05	55.94	37.94	37.94
Total Common Shares Outstanding	69.42	56.05	55.94	37.94	37.94
Working Capital	35,330	20,796	28,772	31,640	48,165
Book Value Per Share	988.87	770.36	857.70	1300.44	1793.43
Tangible Book Value	52,170	42,206	47,538	48,295	67,048
Tangible Book Value Per Share	751.53	752.96	849.83	1273.00	1767.30
Land	3,927	3,927	8,249	7,984	7,984
Buildings	9,241	9,241	10,920	10,596	10,596
Machinery	691.99	414.67	595.05	590.8	533.4
Construction In Progress	176.92	-	310.22	23.52	50.96

Source: S&P Global Market Intelligence. Standard template. Financial Sources.